Macular Edema, Retinal Vein Occlusion
Conditions
Keywords
Macular edema, Retinal Vein Occlusion, Bevacizumab
Brief summary
Lack of an effective treatment for macular edema secondary to central retinal vein occlusion and the bad response to grid laser treatment in patients with macular edema secondary to branch retinal vein occlusion, together with the high incidence of the pathology and the great functional loss in the patients that suffer from it has motivated the search for new therapeutic approaches. In recent times, intravitreal bevacizumab has been tested in clinical practice in small series of patients with this pathology, whether as first treatment or after failure of grid laser treatment with good functional results in short series. However, no retreatment information is available, although preliminary results from published series are good.
Interventions
Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
DRUGSham Avastin Intravitreal Injection
Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
Sponsors
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient male or female 18 years old or more * Foveal macular edema secondary to Retinal Vein Occlusion confirmed by Fluorescein angiography and Optical Coherence Tomography, with a subcentral field thickness of at least 250 microns * Patients with best corrected visual acuity loss within the last 6 months of evolution, caused by the macular edema as stated by investigator´s judgement. * Best corrected visual acuity tested by ETDRS within 20/40 and 20/400 in the study eye. * Signed Informed consent. * Signed Data Protection Consent. * Negative pregnancy test before entering the study for childbearing potential women, who must commit to use a medically accepted contraceptive method for the whole study. * Macular Subcentral field assessed by Ocular coherence tomography of at least 250 microns thick. * No presence of eye opacities that may prevent fundus exploration. No condition that may prevent correct eye dilation. * No known allergy to fluorescein. * Only an eye per patient will be included in the study,even if both eyes have the pathology.
Exclusion criteria
* Macular edema secondary to any other condition such as: diabetes retinopathy, hypertension, Juxtafoveal telangiectasia, ... * Any previous treatment for macular edema such as photocoagulation, vitrectomy, triamcinolone, radial optic neurotomy, ... in the study eye. * Any ocular illness thay may be associated to increased/high levels of VEGF (Age related macular degeneration, Diabetes retinopathy, Uveitis, ...) * Systemical illnesses thay may be associated to increased/high levels of VEGF (e.g. tumours). * Medical history of brain vascular episodes (stroke), ictus, angor pectoris or myocardial infarct within 3 months before study inclusion. * Pregnancy or nursing. * Hypersensibility known or suspected to Bevacizumab, his excipients or any related molecule. * Uncontrolled hypertension refractary to medical treatment. * Participation in any other trial or study within the last 3 months (minerals and vitamins excluded) or treatment with anti-VEGF in the non-study eye within the previous 3 months. * Tractional maculopathy and/or epiretinal membrane assessed by Ocular Coherence Tomography. * Media opacities that don´t allow correct eye exploration and fundus examination/photographs. * Cataract surgery / Yag capsulotomy within the previous 6 months. * Filtration surgery. * Previous medical history of ocular illnesses as: viral infections, inflammatory pathology, serous central choroidopathy, retinal detachment or any other illness that may have an influence in visual acuity. * Presence of foveal atrophy, severe pigmentary changes, dense subfoveal haemorrhages, confluent subfoveal hard exudates or any other condition that may influence functional recovery of the macular edema. * Cataract that may be responsible for additional visual acuity loss of more than 2/10. * Medically uncontrolled intraocular pressure higher than 25 mm Hg. * External ocular illnesses active at inclusion as: conjunctivitis, blepharitis, eye sore, ...
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity assessed as described in the Early Treatment for Diabetes Retinopathy Study (ETDRS) | 1 month |
Secondary
| Measure | Time frame |
|---|---|
| Macular Subcentral Field Thickness assessed by Ocular coherence tomography | 1 month |
Countries
Spain
Outcome results
None listed